about
Treatment for inclusion body myositisMitochondrial disease in adults: what's old and what's new?Mitochondrial dysfunction in inflammatory bowel diseaseMitochondrial geneticsLeber hereditary optic neuropathy: current perspectivesMitochondrial transfer: Implications for assisted reproductive technologiesPrimary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and TreatmentToward a therapy for mitochondrial diseaseIs there treatment for Leber hereditary optic neuropathy?Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management.Autism in the Son of a Woman with Mitochondrial Myopathy and Dysautonomia: A Case Report.Treatment strategies for inherited optic neuropathies: past, present and futureThe impact of lifestyle modifications, diet, and vitamin supplementation on natural fertility.Quantification of gait in mitochondrial m.3243A > G patients: a validation study.Inhibition of ATPIF1 ameliorates severe mitochondrial respiratory chain dysfunction in mammalian cells.Neuroglobin gene therapy prevents optic atrophy and preserves durably visual function in Harlequin mice.Use of the Ketogenic Diet to Treat Intractable Epilepsy in Mitochondrial DisordersPARP inhibition delays progression of mitochondrial encephalopathy in mice.LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: biodistribution and toxicology profile.Stable nuclear expression of ATP8 and ATP6 genes rescues a mtDNA Complex V null mutantSafety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial.Mitochondrial DNA: impacting central and peripheral nervous systems.Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units.Structural analysis of mitochondrial mutations reveals a role for bigenomic protein interactions in human diseaseAutism and intellectual disability associated with mitochondrial disease and hyperlactacidemia.Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss.Cell-permeable protein therapy for complex I dysfunctionAn Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate SynthesisCell-permeable succinate prodrugs bypass mitochondrial complex I deficiencyExtra-ocular muscle MRI in genetically-defined mitochondrial diseaseMitochondrial disease: genetics and management.Preventing the transmission of pathogenic mitochondrial DNA mutations: Can we achieve long-term benefits from germ-line gene transfer?The elusive magic pill: finding effective therapies for mitochondrial disordersDrug development for rare mitochondrial disordersMitochondrial disease in childhood: mtDNA encoded.Review of clinical trials for mitochondrial disorders: 1997-2012.The pleiotropic effects of decanoic acid treatment on mitochondrial function in fibroblasts from patients with complex I deficient Leigh syndrome.Hypoxia as a therapy for mitochondrial disease.Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers.Emerging therapies for mitochondrial disorders.
P2860
Q24186948-029767A6-2F4C-4E8B-80A5-33E5DEC18BE2Q26776417-ED044D7A-7E67-495C-ADC5-003E406392D9Q26781311-BB7B3014-9ACB-4245-8F06-8DF893755AEDQ26849285-C5FBE4CC-3B03-44AC-8D74-46B6B8B1BD58Q26863599-3575BE6C-7061-46E1-A847-4084417E8154Q28066343-237CE906-13EF-45DA-96DC-D4D84DF78B49Q28078384-8B1EAFF6-C5A2-4B7E-B1E1-2C7FE17BA014Q28080024-C6FBB76C-2894-4BB9-8EF4-94FA17FF53BBQ28081486-48FFE6F2-AF2E-4C70-8F3D-DB5452B9D843Q30459704-20E7232D-6F96-44A5-9E8F-BAFF0368ECF6Q33166525-0A9DDD96-3C03-4246-AF65-A261205501A1Q33595163-A56EFDA2-A066-4F08-9872-04852B466077Q33655051-34EB0023-4E4F-406B-8D43-D9936C78AA38Q33691343-5C281BF9-AFEA-45FC-A9EF-0A9E02A192CAQ33696265-78306373-FD8E-4CEA-93D5-076CF4E5E06CQ33724242-94750C90-3871-41BA-B37D-2F36CF9AEC51Q33832704-24F65D17-D0D9-4766-9977-E163D3751BDEQ34000773-4FCD7AF6-94B5-44F3-A95B-070D4A508324Q34600009-DC1A322C-43CF-439A-969C-4378256D6965Q34678611-39128914-47FF-4261-A142-D7AFE0A117BCQ34700126-8AF0B39F-6C94-4671-A60F-93BCFFDF99D8Q34737643-5B2F2377-583A-43A6-BA94-F9974264DC2EQ34820081-E0EADB69-4648-4116-8FB6-77A134129610Q34852419-47D73824-85B2-4A61-B8ED-33B6118AD346Q35139145-50DC9176-1385-496A-9DFF-CBBEC3DB0B82Q35651068-CEE0C8D5-8260-4ACD-9EFA-611B39C48679Q35660914-96157F22-D9AB-4FC4-A73F-CC91CD810755Q35908707-FF415671-5E15-4151-AD08-E658F4580468Q36098140-5F96B25A-FA10-4027-B504-32FAC34994DDQ36337385-F52F3F73-4370-433D-ACD6-3036CBDFA0AAQ36492283-F47E7195-B6E9-4001-A4BF-772E74FFF1EDQ36607471-7AFB34D4-9592-4E8F-86FF-810D7410FE5FQ36762813-D8E9F765-6FD7-46DB-A76A-F825A3BB53D9Q36762826-39ED266E-F281-4BD0-8454-1C6563E0B166Q36762842-C4782203-0AF4-445D-AF61-17178BD18202Q36762846-F557CCAF-6654-43B6-9015-253ADFD98B75Q36853449-DCA31FD6-E1F7-4265-9658-A127F768CCBEQ36882394-B5CF3D8D-6210-4D35-BACC-38230E61567EQ36926270-ADE2C79C-CE25-4BC1-9873-BBC23A7CB93FQ36967723-6283FE5C-ED49-43DD-97AA-4D2623EFED87
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Treatment for mitochondrial disorders
@ast
Treatment for mitochondrial disorders
@en
Treatment for mitochondrial disorders
@en-gb
Treatment for mitochondrial disorders
@nl
type
label
Treatment for mitochondrial disorders
@ast
Treatment for mitochondrial disorders
@en
Treatment for mitochondrial disorders
@en-gb
Treatment for mitochondrial disorders
@nl
prefLabel
Treatment for mitochondrial disorders
@ast
Treatment for mitochondrial disorders
@en
Treatment for mitochondrial disorders
@en-gb
Treatment for mitochondrial disorders
@nl
P2093
P2860
P3181
P1476
Treatment for mitochondrial disorders
@en
P2093
David Thorburn
Douglass M Turnbull
Gerald Pfeffer
Kari Majamaa
P2860
P304
P3181
P356
10.1002/14651858.CD004426.PUB3
P407
P577
2012-04-18T00:00:00Z